BOLT BIOTHERAPEUTICS
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates.
BOLT BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.boltbio.com
Total Employee:
11+
Status:
Active
Contact:
(310)909-3218
Email Addresses:
[email protected]
Total Funding:
198.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Genmab
Genmab investment in Post-IPO Equity - Bolt Biotherapeutics
Samsara BioCapital
Samsara BioCapital investment in Series C - Bolt Biotherapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Bolt Biotherapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - Bolt Biotherapeutics
Vivo Capital
Vivo Capital investment in Series C - Bolt Biotherapeutics
Surveyor Capital
Surveyor Capital investment in Series C - Bolt Biotherapeutics
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series C - Bolt Biotherapeutics
Novo Holdings
Novo Holdings investment in Series C - Bolt Biotherapeutics
RA Capital Management
RA Capital Management investment in Series C - Bolt Biotherapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Bolt Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-09 | Bolt Bio Adds Mayo Clinic’s Edith Perez as Chief Medical Officer |
Official Site Inspections
http://www.boltbio.com Semrush global rank: 3.58 M Semrush visits lastest month: 4.04 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bolt Biotherapeutics"
About Us - Bolt Biotherapeutics
Willie Quinn Chief Executive Officer. Willie Quinn, Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2020, bringing extensive …See details»
Bolt Biotherapeutics - Crunchbase Company Profile & Funding
Organization. Bolt Biotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
Bolt Biotherapeutics, Inc. | LinkedIn
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbodyâ„¢ Immune-stimulating Antibody Conjugates (ISAC), a new class of ...See details»
Bolt Biotherapeutics - Craft
Aug 22, 2024 Bolt Biotherapeutics has 4 employees at their 1 location and $7.88 m in annual revenue in FY 2023. See insights on Bolt Biotherapeutics including office locations, …See details»
Patients - Bolt Biotherapeutics Clinical Trials
If you have questions about our clinical trials, please email us at [email protected]. Expanded Access Policy. At this time, participation in clinical trials is the only way to gain …See details»
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
[email protected] . Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] . David Schull Russo Partners, LLC 212-845-4271 …See details»
Genmab and Bolt Biotherapeutics Announce Oncology Research …
Media Release Collaboration to discover and evaluate novel product concepts based on the combination of Genmab’s antibodies and bispecific antibody technologies with Bolt’s …See details»
Bolt Biotherapeutics Reports First Quarter 2024 Results,
May 14, 2024 BOLT BIOTHERAPEUTICS, INC. STATEMENTS OF CASH FLOWS (Unaudited, in thousands) Three Months Ended March 31, 2024 2023 CASH FLOWS FROM OPERATING …See details»
Bolt Biotherapeutics Reports First Quarter 2024 Results, …
May 14, 2024 Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbodyâ„¢ ISAC platform including new clinical candidate BDC- 4182 targeting …See details»
Careers - Lever - Bolt Biotherapeutics
*By applying for or contacting us regarding a job posting, you acknowledge that the personal information you provide will be processed by Bolt Biotherapeutics in order to assess your qualifications for employment consideration and to …See details»
News Release Details - Bolt Biotherapeutics
These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov. Investor Relations and …See details»
Our Science - Bolt Biotherapeutics
Our BDC-3042 product candidate reawakens myeloid cells to attack tumor cells. We discovered an agonist monoclonal antibody that is capable of binding to and activating a pattern …See details»
Bolt Biotherapeutics Announces Clinical Collaboration with
Sep 8, 2021 [email protected]. Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected]. Maggie Beller or David Schull Russo Partners, LLC 646 …See details»
News Release Details - investors.boltbio.com
These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov. Investor Relations and …See details»
Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial …
Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com. Media Contacts: Maggie Beller or David Schull Russo Partners, LLC 646 …See details»
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2021 ...
[email protected]. Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected]. Maggie Beller or David Schull Russo Partners, LLC 646-942 …See details»
Bolt Biotherapeutics to Present Interim Clinical Data on
Dec 2, 2021 [email protected]. Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected]. Maggie Beller or David Schull Russo Partners, LLC 646 …See details»
Pipeline - Bolt Biotherapeutics
BDC-3042. BDC-3042 is a first-in-class antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells. We identified monoclonal antibodies that are capable of binding …See details»
Bolt Biotherapeutics Reports Second Quarter 2021 Financial …
[email protected]. Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected]. Maggie Beller or David Schull Russo Partners, LLC 646-942 …See details»